Discussion
Early data from a Phase 2 clinical trial testing an experimental inhaled treatment for idiopathic pulmonary fibrosis (IPF) against a placebo showed improvements in lung function in about one-third of participants after 12 weeks, according to the treatment’s developer, Rein Therapeutics. However, the findings include people receiving either…